Indaptus Therapeutics (NASDAQ:INDP) Upgraded to Hold at Wall Street Zen

Indaptus Therapeutics (NASDAQ:INDP) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Indaptus Therapeutics currently has an average rating of “Sell”.

Indaptus Therapeutics Price Performance

Shares of NASDAQ:INDP opened at $3.38 on Friday. The firm has a market capitalization of $382.98 million, a PE ratio of -0.22 and a beta of 1.25. The business has a 50-day moving average of $2.63 and a two-hundred day moving average of $2.35. Indaptus Therapeutics has a 12 month low of $0.92 and a 12 month high of $13.40.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is currently owned by institutional investors.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.